Fibroblast Growth Factor 10

01/01/2021 - "The protective effects of fibroblast growth factor 10 against hepatic ischemia-reperfusion injury in mice."
01/01/2023 - "Fibroblast growth factor 10 ameliorates renal ischaemia-reperfusion injury by attenuating mitochondrial damage."
01/01/2020 - "Fibroblast Growth Factor 10 Attenuates Renal Damage by Regulating Endoplasmic Reticulum Stress After Ischemia-Reperfusion Injury."

12/15/2004 - "Repifermin given before and after auto-HSCT seems to be active in reducing mucositis, but a larger trial will be necessary to determine the efficacy of repifermin with this dose schedule."
12/15/2004 - "Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation."
07/01/2001 - "Furthermore, the analysts predicted sales of 6.8 million dollars for repifermin's mucositis indication and, for ulcerative colitis, sales of 27.3 million dollars in 2004 and 54.8 million dollars in 2005. "
09/01/2002 - "This is critical to the safety profile of repifermin, since it is currently in phase II clinical trials for the treatment of cancer patients with mucositis resulting from chemo- or radiotherapy."
07/01/2001 - "In May 2001, UBS Warburg predicted that HGS would receive approval of repifermin for the treatment of venous ulcers by yearend 2004, mucositis in 2005, and ulcerative colitis in the second half of 2004 [412015]. "

09/01/2001 - "A randomized, double-blind, parallel-group, placebo-controlled, multicenter study was conducted to evaluate the safety and efficacy of topical repifermin treatment, for 12 weeks, in the healing of chronic venous ulcers in 94 patients. "
07/01/2001 - "In May 2001, UBS Warburg valued repifermin's worldwide market at 2 billion dollars for treating venous ulcers and predicted sales of 33 million dollars in 2004 and 118 million dollars in 2005 for this indication. "
07/01/2001 - "In May 2001, UBS Warburg predicted that HGS would receive approval of repifermin for the treatment of venous ulcers by yearend 2004, mucositis in 2005, and ulcerative colitis in the second half of 2004 [412015]. "
09/01/2001 - "Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers."

06/01/2003 - "Intravenous repifermin at a dose of 1-50 microg/kg was very well tolerated, but there was no evidence that repifermin was effective for the treatment of active ulcerative colitis at these doses. "
06/01/2003 - "To evaluate repifermin for the treatment of active ulcerative colitis. "
07/01/2001 - "Furthermore, the analysts predicted sales of 6.8 million dollars for repifermin's mucositis indication and, for ulcerative colitis, sales of 27.3 million dollars in 2004 and 54.8 million dollars in 2005. "
07/01/2001 - "In May 2001, UBS Warburg predicted that HGS would receive approval of repifermin for the treatment of venous ulcers by yearend 2004, mucositis in 2005, and ulcerative colitis in the second half of 2004 [412015]. "
06/01/2003 - "Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial."

01/01/2003 - "The results suggest that repifermin therapy may improve the mucosal electrogenic transport that is impaired during colitis."
01/01/2003 - "The aim of this study was to determine whether repifermin, a truncated form of recombinant human KGF-2, reverses abnormalities in colonic mucosal transport in a murine model of dextran sulfate sodium (DSS)-induced colitis. "
01/01/2003 - "Efficacy of repifermin (keratinocyte growth factor-2) against abnormalities in gastrointestinal mucosal transport in a murine model of colitis."
06/01/2003 - "Repifermin (keratinocyte growth factor-2) has been shown to reduce inflammation in animal models of colitis. "